Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment
JOURNAL OF CLINICAL NEUROSCIENCE, cilt.17, sa.10, ss.1256-1259, 2010 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 10
- Basım Tarihi: 2010
- Doi Numarası: 10.1016/j.jocn.2010.01.045
- Dergi Adı: JOURNAL OF CLINICAL NEUROSCIENCE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1256-1259
- Anahtar Kelimeler: Body mass index, HDL cholesterol, Insulin resistance, Leptin topiramate, Waist circumference, HOMEOSTASIS MODEL ASSESSMENT, ANTIEPILEPTIC DRUGS, WEIGHT-LOSS, RISK-FACTORS, DOUBLE-BLIND, BODY-WEIGHT, CARBAMAZEPINE, LIPOPROTEINS, MORTALITY, CHILDREN
- Akdeniz Üniversitesi Adresli: Hayır
Özet
We aimed to investigate the effects of topiramate monotherapy on anthropometric indexes, insulin resistance, and serum leptin and lipid levels in 33 premenopausal women (mean age +/- standard deviation: 26.7 +/- 7.1 years) with cryptogenic epilepsy. Body mass index (BMI), waist circumference and serum leptin, insulin and lipid levels were measured at baseline and at 6 months after initiation of topiramate. We found reductions in BMI (p < 0.001), waist circumference (p < 0.001) and serum high-density lipoprotein (HDL) cholesterol levels (p = 0.011). We also found significant improvements in insulin resistance (p = 0.023), but not in serum leptin levels (p = 0.45). Our results suggest that topiramate treatment in women with epilepsy is associated with reduced BMI and waist circumference and improvement in insulin resistance; however, according to our data, topiramate treatment is also associated with lower HDL cholesterol levels, which may substantially increase vascular disease. (C) 2010 Elsevier Ltd. All rights reserved.